Biogen Idec Inc. (NASDAQ:BIIB) and their partner Swedish Orphan Biovitrum AB recently announced that they will donate one billion international units of Factor VIII therapy for humanitarian aid programs. Biogen Idec Inc (NASDAQ:BIIB) net profit margin is 25.00% and weekly performance is 1.63%. On last trading day company shares ended up $291.32. Analysts mean target price for the company is $345.53. Biogen Idec Inc (NASDAQ:BIIB) distance from 50-day simple moving average (SMA50) is -4.38%.
Biodel Inc. (NASDAQ:BIOD)’s shares were down 3.5% immediately after the company reported second quarter fiscal 2014 report. Overall, shares are down 6.9% since the company released second quarter results. The company reported a loss of 29 cents per share, narrower than the year-ago loss of 37 cents but wider than the Zacks Consensus Estimate of a loss of 26 cents per share. Biodel Inc (NASDAQ:BIOD) shares fell -1.64% in last trading session and ended the day on $2.11. BIOD return on assets is -47.10%. Biodel Inc (NASDAQ:BIOD) quarterly performance is -31.43%.
Gilead Sciences Inc. (NASDAQ:GILD), another biotech, develops antiviral drugs to treat hepatitis C, HIV and influenza. With recent acquisitions, it’s also built a pipeline of drugs to treat lung diseases. It has a $124.3 billion market cap and 99 Composite Rating. Over the last four quarters, its EPS growth rate accelerated from 0% to 4%, 10% and surged to 208% last quarter. Consensus of 28 analysts polled by Thomson Reuters is for a 216% hike this quarter. Shares rose 1%. Gilead Sciences, Inc. (NASDAQ:GILD) shares moved up 0.87% in last trading session and was closed at $80.80, while trading in range of $79.22 – $80.84. Gilead Sciences, Inc. (NASDAQ:GILD) year to date (YTD) performance is 7.59%.
Galena Biopharma Inc (NASDAQ:GALE), a bio pharmaceutical company that is developing as well as commercializing many innovative and targeted oncology treatments which address many major and unmet medical needs in the advancement of cancer care, announced that the Department of Defense will now provide it with funding towards its new clinical-trial with NeuVax in prevention of breast cancer recurrence in the high-risk HER2 3+ patients. This grant, which is a Breast Cancer Research Program Breakthrough Award, has been obtained by Elizabeth A. Mittendorf, M.D., the Associate Professor at the Department of Surgical Oncology, at The University of Texas’ MD Anderson Cancer Center. Galena Biopharma Inc (NASDAQ:GALE) ended the last trading day at $2.17. Company weekly volatility is calculated as 6.34% and price to cash ratio as 4.89. Galena Biopharma Inc (NASDAQ:GALE) showed a negative weekly performance of -6.87%.
US pharmaceuticals and healthcare products company Abbott Laboratories (NYSE:ABT) will acquire CFR in a $2.9bn deal that will more than double Abbott Laboratories (NYSE:ABT)’s branded generic drugs business in the fast-growing Latin American market. The deal comes when mergers in the health industry have surged, with analysts looking to the expansion of generic drugs in emerging markets. Abbott Laboratories (NYSE:ABT) net profit margin is 13.60% and weekly performance is 0.18%. On last trading day company shares ended up $39.06. Analysts mean target price for the company is $41.32. Abbott Laboratories (NYSE:ABT) distance from 50-day simple moving average (SMA50) is 1.21%.
Leave a Reply